JP2019534261A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019534261A5 JP2019534261A5 JP2019518440A JP2019518440A JP2019534261A5 JP 2019534261 A5 JP2019534261 A5 JP 2019534261A5 JP 2019518440 A JP2019518440 A JP 2019518440A JP 2019518440 A JP2019518440 A JP 2019518440A JP 2019534261 A5 JP2019534261 A5 JP 2019534261A5
- Authority
- JP
- Japan
- Prior art keywords
- cancer
- salt
- compound according
- acceptable
- methyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 0 CCC*(CC**c1n*(*)c(C(*=C2)=**2N*)[n]1)C(C(*)(*)*(CC1)CC1(CC*1C2=*CC(C(**)=**3(C)C)=C3C=C2)C1=O)=O Chemical compound CCC*(CC**c1n*(*)c(C(*=C2)=**2N*)[n]1)C(C(*)(*)*(CC1)CC1(CC*1C2=*CC(C(**)=**3(C)C)=C3C=C2)C1=O)=O 0.000 description 3
- MBVCTQKXEGCCCL-UHFFFAOYSA-N CC(O1)=NN(C)C1=O Chemical compound CC(O1)=NN(C)C1=O MBVCTQKXEGCCCL-UHFFFAOYSA-N 0.000 description 1
- HZMBHUAOZYMRMM-UHFFFAOYSA-N CCCN(CCC(N(CC)c(nc12)ccc1[nH]nc2-c1ccc2[nH]nc(C)c2c1)=O)CC(N(CC1)CC=C1c(cc1)ccc1-c1n[n](C)cn1)=O Chemical compound CCCN(CCC(N(CC)c(nc12)ccc1[nH]nc2-c1ccc2[nH]nc(C)c2c1)=O)CC(N(CC1)CC=C1c(cc1)ccc1-c1n[n](C)cn1)=O HZMBHUAOZYMRMM-UHFFFAOYSA-N 0.000 description 1
- GNZLMOPUFWAWCM-UHFFFAOYSA-N CCN(C(C1(C)CN(CC(N(CC2)CC=C2c(nc2)ccc2-c2n[n](C)cn2)=O)CC1)=O)c(cc1)nc2c1[nH]nc2-c(cc1)ccc1OC(C)C Chemical compound CCN(C(C1(C)CN(CC(N(CC2)CC=C2c(nc2)ccc2-c2n[n](C)cn2)=O)CC1)=O)c(cc1)nc2c1[nH]nc2-c(cc1)ccc1OC(C)C GNZLMOPUFWAWCM-UHFFFAOYSA-N 0.000 description 1
- QXAXJRFSRONTIN-RMVMEJTISA-N CCN(C(C1)C=Cc2c1c(-c(nc1)ccc1[F]C)n[nH]2)C([C@H]1CN(CC(N(CC2)CCN2c(nc2)ccc2-c2n[n](C)cn2)=O)CC1)=O Chemical compound CCN(C(C1)C=Cc2c1c(-c(nc1)ccc1[F]C)n[nH]2)C([C@H]1CN(CC(N(CC2)CCN2c(nc2)ccc2-c2n[n](C)cn2)=O)CC1)=O QXAXJRFSRONTIN-RMVMEJTISA-N 0.000 description 1
- DCSWJQOSZKSFEZ-UHFFFAOYSA-N CCN(C(C1=CN(CC(N(CC2)CCN2c(nc2)ccc2-c2n[n](C)cn2)=O)CC1)=O)c(cc1)nc2c1[nH]nc2-c(cn1)ccc1OC Chemical compound CCN(C(C1=CN(CC(N(CC2)CCN2c(nc2)ccc2-c2n[n](C)cn2)=O)CC1)=O)c(cc1)nc2c1[nH]nc2-c(cn1)ccc1OC DCSWJQOSZKSFEZ-UHFFFAOYSA-N 0.000 description 1
- IAYZAOMOUHPOLI-UHFFFAOYSA-N CCN(C(C1CN(CC(N(CC2)CC=C2c(cc2)ccc2-c2n[n](C)cn2)=O)CC1)=O)c(cc1)nc2c1[nH]nc2-c1ccc2[o]nc(C)c2c1 Chemical compound CCN(C(C1CN(CC(N(CC2)CC=C2c(cc2)ccc2-c2n[n](C)cn2)=O)CC1)=O)c(cc1)nc2c1[nH]nc2-c1ccc2[o]nc(C)c2c1 IAYZAOMOUHPOLI-UHFFFAOYSA-N 0.000 description 1
- RUBGBTVEESZOCD-QASNXKAYSA-N CCN(C(C1[C@@H](C)CN(CC(N(CC2)CC=C2c(cc2)ccc2-c2n[n](C)cn2)=O)C1)=O)c(nc12)ccc1[nH]nc2-c(c(F)c1)ccc1[ClH]C Chemical compound CCN(C(C1[C@@H](C)CN(CC(N(CC2)CC=C2c(cc2)ccc2-c2n[n](C)cn2)=O)C1)=O)c(nc12)ccc1[nH]nc2-c(c(F)c1)ccc1[ClH]C RUBGBTVEESZOCD-QASNXKAYSA-N 0.000 description 1
- NDPMJKQHUDUIKM-SSEXGKCCSA-N CCN(C([C@H]1CN(CC(N(CC2)CC=C2c(cc2)ccc2-c2n[n](C)cn2)=O)CC1)=O)c(cc1)nc(C(c(cc2)ccc2OC(C)C)=N)c1N Chemical compound CCN(C([C@H]1CN(CC(N(CC2)CC=C2c(cc2)ccc2-c2n[n](C)cn2)=O)CC1)=O)c(cc1)nc(C(c(cc2)ccc2OC(C)C)=N)c1N NDPMJKQHUDUIKM-SSEXGKCCSA-N 0.000 description 1
- ITMAOYQVJCZFGA-SSEXGKCCSA-N CCN(C([C@H]1CN(CC(N(CC2)CC=C2c(cc2)ccc2-c2n[n](C)cn2)=O)CC1)=O)c(cc1)nc2c1[nH]nc2-c(cc1)cc(OC)c1OC(C)C Chemical compound CCN(C([C@H]1CN(CC(N(CC2)CC=C2c(cc2)ccc2-c2n[n](C)cn2)=O)CC1)=O)c(cc1)nc2c1[nH]nc2-c(cc1)cc(OC)c1OC(C)C ITMAOYQVJCZFGA-SSEXGKCCSA-N 0.000 description 1
- DVYAVLSWFJARNY-MUUNZHRXSA-N CCN(C([C@H]1CN(CC(N(CC2)CC=C2c(cc2)ccc2-c2n[n](C)cn2)=O)CC1)=O)c(cc12)ccc1[nH]nc2-c(nc1OC)ccc1OC1CC1 Chemical compound CCN(C([C@H]1CN(CC(N(CC2)CC=C2c(cc2)ccc2-c2n[n](C)cn2)=O)CC1)=O)c(cc12)ccc1[nH]nc2-c(nc1OC)ccc1OC1CC1 DVYAVLSWFJARNY-MUUNZHRXSA-N 0.000 description 1
- MDKYGHNCPWMSJJ-WJOKGBTCSA-N CCN(C([C@H]1CN(CC(N(CC2)CC=C2c(cc2)ccc2C(/N=C\NC)=N)=O)CC1)=O)c(cc1)cc2c1[nH]nc2-c(cc1)ccc1OC(C)C Chemical compound CCN(C([C@H]1CN(CC(N(CC2)CC=C2c(cc2)ccc2C(/N=C\NC)=N)=O)CC1)=O)c(cc1)cc2c1[nH]nc2-c(cc1)ccc1OC(C)C MDKYGHNCPWMSJJ-WJOKGBTCSA-N 0.000 description 1
- CULMORASYYAQGQ-GDLZYMKVSA-N CCN(C([C@H]1CN(CC(N(CC2)CC=C2c(cc2)ccc2C(/N=C\NC)=N)=O)CC1)=O)c(cc1)cc2c1[nH]nc2-c(nc1N2CCCC2)ccc1F Chemical compound CCN(C([C@H]1CN(CC(N(CC2)CC=C2c(cc2)ccc2C(/N=C\NC)=N)=O)CC1)=O)c(cc1)cc2c1[nH]nc2-c(nc1N2CCCC2)ccc1F CULMORASYYAQGQ-GDLZYMKVSA-N 0.000 description 1
- HSLXVKOJYMNMNE-SSEXGKCCSA-N CCN(C([C@H]1CN(CC(N(CC2)CC=C2c(cc2)ccc2C(/N=C\NC)=N)=O)CC1)=O)c(cc1)nc2c1[nH]nc2-c(cc1)ccc1C#[N]C Chemical compound CCN(C([C@H]1CN(CC(N(CC2)CC=C2c(cc2)ccc2C(/N=C\NC)=N)=O)CC1)=O)c(cc1)nc2c1[nH]nc2-c(cc1)ccc1C#[N]C HSLXVKOJYMNMNE-SSEXGKCCSA-N 0.000 description 1
- RRAOYXXXEMFIES-MUUNZHRXSA-O CCN(C([C@H]1CN(CC(N(CC2)CC=C2c(cc2)ccc2C(/N=C\NC)=[NH2+])=O)CC1)=O)c(cc12)ccc1[nH]nc2-c(nc1)ccc1C#N Chemical compound CCN(C([C@H]1CN(CC(N(CC2)CC=C2c(cc2)ccc2C(/N=C\NC)=[NH2+])=O)CC1)=O)c(cc12)ccc1[nH]nc2-c(nc1)ccc1C#N RRAOYXXXEMFIES-MUUNZHRXSA-O 0.000 description 1
- LYEJXIHOCDMNLO-HHHXNRCGSA-N CCN(C([C@H]1CN(CC(N(CC2)CC=C2c(cc2)ccc2C(O2)=NN(C)C2=O)=O)CC1)=O)c(nc12)ccc1[nH]nc2-c1ccc(C)nc1 Chemical compound CCN(C([C@H]1CN(CC(N(CC2)CC=C2c(cc2)ccc2C(O2)=NN(C)C2=O)=O)CC1)=O)c(nc12)ccc1[nH]nc2-c1ccc(C)nc1 LYEJXIHOCDMNLO-HHHXNRCGSA-N 0.000 description 1
- HAJBINBHTWYDAK-MUUNZHRXSA-N CCN(C([C@H]1CN(CC(N(CC2)CC=C2c2ccc(-c3n[n](C)cn3)nc2)=O)CC1)=O)c(nc12)ccc1[nH]nc2-c(cc1)ccc1OC(C)C Chemical compound CCN(C([C@H]1CN(CC(N(CC2)CC=C2c2ccc(-c3n[n](C)cn3)nc2)=O)CC1)=O)c(nc12)ccc1[nH]nc2-c(cc1)ccc1OC(C)C HAJBINBHTWYDAK-MUUNZHRXSA-N 0.000 description 1
- WTKZDLSBVYKJJB-RUZDIDTESA-N CCN(C([C@H]1CN(CC(N(CC2)CCN2c(nc2)ccc2-c2n[n](C)cn2)=O)CC1)=O)c(nc12)ccc1[nH]nc2-c1ccnc(C)c1 Chemical compound CCN(C([C@H]1CN(CC(N(CC2)CCN2c(nc2)ccc2-c2n[n](C)cn2)=O)CC1)=O)c(nc12)ccc1[nH]nc2-c1ccnc(C)c1 WTKZDLSBVYKJJB-RUZDIDTESA-N 0.000 description 1
- KJUGBSAKKMBCRD-LBNVMWSVSA-N CCN(C([C@H]1CN(CC(N(CC2)[C@@H](C)CN2c(cc2)ccc2-c2n[n](C)cn2)=O)CC1)=O)c(nc12)ccc1[nH]nc2-c(cc1)cnc1OC(C)C Chemical compound CCN(C([C@H]1CN(CC(N(CC2)[C@@H](C)CN2c(cc2)ccc2-c2n[n](C)cn2)=O)CC1)=O)c(nc12)ccc1[nH]nc2-c(cc1)cnc1OC(C)C KJUGBSAKKMBCRD-LBNVMWSVSA-N 0.000 description 1
- KJUGBSAKKMBCRD-LEAFIULHSA-N CCN(C([C@H]1CN(CC(N(CC2)[C@H](C)CN2c(cc2)ccc2-c2n[n](C)cn2)=O)CC1)=O)c(cc1)nc2c1[nH]nc2-c(cc1)cnc1OC(C)C Chemical compound CCN(C([C@H]1CN(CC(N(CC2)[C@H](C)CN2c(cc2)ccc2-c2n[n](C)cn2)=O)CC1)=O)c(cc1)nc2c1[nH]nc2-c(cc1)cnc1OC(C)C KJUGBSAKKMBCRD-LEAFIULHSA-N 0.000 description 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2021154677A JP2021193138A (ja) | 2016-10-05 | 2021-09-22 | スピロ環化合物 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662404668P | 2016-10-05 | 2016-10-05 | |
| US62/404,668 | 2016-10-05 | ||
| PCT/US2017/054865 WO2018067512A1 (en) | 2016-10-05 | 2017-10-03 | Spirocyclic compounds |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021154677A Division JP2021193138A (ja) | 2016-10-05 | 2021-09-22 | スピロ環化合物 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2019534261A JP2019534261A (ja) | 2019-11-28 |
| JP2019534261A5 true JP2019534261A5 (cg-RX-API-DMAC7.html) | 2020-11-12 |
| JP6949952B2 JP6949952B2 (ja) | 2021-10-13 |
Family
ID=61831517
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019518440A Expired - Fee Related JP6949952B2 (ja) | 2016-10-05 | 2017-10-03 | スピロ環化合物 |
| JP2021154677A Pending JP2021193138A (ja) | 2016-10-05 | 2021-09-22 | スピロ環化合物 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021154677A Pending JP2021193138A (ja) | 2016-10-05 | 2021-09-22 | スピロ環化合物 |
Country Status (13)
| Country | Link |
|---|---|
| US (2) | US10934304B2 (cg-RX-API-DMAC7.html) |
| EP (1) | EP3523306A4 (cg-RX-API-DMAC7.html) |
| JP (2) | JP6949952B2 (cg-RX-API-DMAC7.html) |
| KR (1) | KR20190075931A (cg-RX-API-DMAC7.html) |
| CN (1) | CN109890827A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2017339890A1 (cg-RX-API-DMAC7.html) |
| BR (1) | BR112019005305A2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3037064A1 (cg-RX-API-DMAC7.html) |
| IL (1) | IL265752A (cg-RX-API-DMAC7.html) |
| MX (1) | MX2019003938A (cg-RX-API-DMAC7.html) |
| RU (1) | RU2019107667A (cg-RX-API-DMAC7.html) |
| TW (1) | TW201817732A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2018067512A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3495367B1 (en) | 2012-06-13 | 2020-09-30 | Incyte Holdings Corporation | Substituted tricyclic compounds as fgfr inhibitors |
| DK2986610T5 (en) | 2013-04-19 | 2018-12-10 | Incyte Holdings Corp | BICYCLIC HETEROCYCLES AS FGFR INHIBITORS |
| CR20170390A (es) | 2015-02-20 | 2017-10-23 | Incyte Holdings Corp | Heterociclos biciclicos como inhibidores de fgfr |
| MA41551A (fr) | 2015-02-20 | 2017-12-26 | Incyte Corp | Hétérocycles bicycliques utilisés en tant qu'inhibiteurs de fgfr4 |
| SMT202000279T1 (it) | 2015-04-03 | 2020-07-08 | Recurium Ip Holdings Llc | Composti spirociclici |
| AR111960A1 (es) | 2017-05-26 | 2019-09-04 | Incyte Corp | Formas cristalinas de un inhibidor de fgfr y procesos para su preparación |
| CN112566912A (zh) | 2018-05-04 | 2021-03-26 | 因赛特公司 | Fgfr抑制剂的盐 |
| US11466004B2 (en) | 2018-05-04 | 2022-10-11 | Incyte Corporation | Solid forms of an FGFR inhibitor and processes for preparing the same |
| EP3846904B1 (en) * | 2018-09-07 | 2023-05-31 | Merck Patent GmbH | 5-morpholin-4-yl-pyrazolo[4,3-b]pyridine derivatives |
| WO2020185532A1 (en) | 2019-03-08 | 2020-09-17 | Incyte Corporation | Methods of treating cancer with an fgfr inhibitor |
| US11591329B2 (en) | 2019-07-09 | 2023-02-28 | Incyte Corporation | Bicyclic heterocycles as FGFR inhibitors |
| US12122767B2 (en) | 2019-10-01 | 2024-10-22 | Incyte Corporation | Bicyclic heterocycles as FGFR inhibitors |
| GEAP202415945A (en) | 2019-10-14 | 2024-04-25 | Incyte Corp | Bicyclic heterocycles as fgfr inhibitors |
| WO2021076728A1 (en) | 2019-10-16 | 2021-04-22 | Incyte Corporation | Bicyclic heterocycles as fgfr inhibitors |
| BR112022010664A2 (pt) | 2019-12-04 | 2022-08-16 | Incyte Corp | Derivados de um inibidor de fgfr |
| EP4069696A1 (en) | 2019-12-04 | 2022-10-12 | Incyte Corporation | Tricyclic heterocycles as fgfr inhibitors |
| CN110922421B (zh) * | 2019-12-17 | 2023-05-05 | 安徽英特美科技有限公司 | 一种n-甲基-1,2,5,6-四氢吡啶-4-硼酸频哪醇酯的合成方法 |
| US12012409B2 (en) | 2020-01-15 | 2024-06-18 | Incyte Corporation | Bicyclic heterocycles as FGFR inhibitors |
| TW202304459A (zh) | 2021-04-12 | 2023-02-01 | 美商英塞特公司 | 包含ｆｇｆｒ抑制劑及ｎｅｃｔｉｎ－４靶向劑之組合療法 |
| WO2022261159A1 (en) | 2021-06-09 | 2022-12-15 | Incyte Corporation | Tricyclic heterocycles as fgfr inhibitors |
| JP2024522189A (ja) | 2021-06-09 | 2024-06-11 | インサイト・コーポレイション | Ｆｇｆｒ阻害剤としての三環式ヘテロ環 |
| WO2025096858A1 (en) * | 2023-10-31 | 2025-05-08 | C4 Therapeutics, Inc. | Compounds for the degradation of mutant braf |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PT3305776T (pt) * | 2004-05-14 | 2019-12-17 | Vertex Pharma | Compostos de pirrol como inibidores de proteína quinaseserk e composições farmacêuticas que contêm esses compostos |
| RS51981B (sr) | 2005-12-13 | 2012-02-29 | Schering Corporation | Policiklični derivati indazola koji su inhibitori erk |
| JP5380296B2 (ja) | 2006-11-17 | 2014-01-08 | ポリエラ コーポレイション | ジイミド系半導体材料ならびにジイミド系半導体材料を調製および使用する方法 |
| CA2691417A1 (en) * | 2007-06-18 | 2008-12-24 | Schering Corporation | Heterocyclic compounds and use thereof as erk inhibitors |
| US20110166124A1 (en) | 2008-07-23 | 2011-07-07 | Mccormick Kevin D | Tricyclic spirocycle derivatives and methods of use |
| EP3296398A1 (en) | 2009-12-07 | 2018-03-21 | Arbutus Biopharma Corporation | Compositions for nucleic acid delivery |
| ES2609579T3 (es) | 2011-08-29 | 2017-04-21 | VIIV Healthcare UK (No.5) Limited | Derivados espiro de diamina bicíclica como inhibidores de la unión del VIH |
| CN103130775B (zh) | 2011-11-22 | 2015-09-30 | 山东亨利医药科技有限责任公司 | 作为酪氨酸激酶抑制剂的吲哚满酮衍生物 |
| US8987264B2 (en) * | 2012-11-09 | 2015-03-24 | Bristol-Myers Squibb Company | 1,3,5-triazine derivatives of spiro bicyclic oxalamide-compounds for treatment of hepatitis C |
| CA2903431C (en) | 2013-03-14 | 2022-12-06 | Kalyra Pharmaceuticals, Inc. | Bicyclopentane analgesic compounds |
| ES2700200T3 (es) | 2014-12-22 | 2019-02-14 | Lilly Co Eli | Inhibidores de ERK |
| CN105732636B (zh) * | 2014-12-30 | 2020-04-21 | 广东东阳光药业有限公司 | 杂芳化合物及其在药物中的应用 |
| SMT202000279T1 (it) * | 2015-04-03 | 2020-07-08 | Recurium Ip Holdings Llc | Composti spirociclici |
-
2017
- 2017-10-03 CN CN201780067175.6A patent/CN109890827A/zh active Pending
- 2017-10-03 EP EP17858989.1A patent/EP3523306A4/en not_active Withdrawn
- 2017-10-03 US US16/336,854 patent/US10934304B2/en not_active Expired - Fee Related
- 2017-10-03 AU AU2017339890A patent/AU2017339890A1/en not_active Abandoned
- 2017-10-03 JP JP2019518440A patent/JP6949952B2/ja not_active Expired - Fee Related
- 2017-10-03 MX MX2019003938A patent/MX2019003938A/es unknown
- 2017-10-03 BR BR112019005305A patent/BR112019005305A2/pt not_active Application Discontinuation
- 2017-10-03 WO PCT/US2017/054865 patent/WO2018067512A1/en not_active Ceased
- 2017-10-03 RU RU2019107667A patent/RU2019107667A/ru not_active Application Discontinuation
- 2017-10-03 CA CA3037064A patent/CA3037064A1/en not_active Abandoned
- 2017-10-03 KR KR1020197012021A patent/KR20190075931A/ko not_active Ceased
- 2017-10-05 TW TW106134299A patent/TW201817732A/zh unknown
-
2019
- 2019-04-01 IL IL265752A patent/IL265752A/en unknown
-
2020
- 2020-12-18 US US17/127,710 patent/US20210115058A1/en not_active Abandoned
-
2021
- 2021-09-22 JP JP2021154677A patent/JP2021193138A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2019534261A5 (cg-RX-API-DMAC7.html) | ||
| RU2019107667A (ru) | Спироциклические соединения | |
| JP2024102236A5 (cg-RX-API-DMAC7.html) | ||
| US20240092794A1 (en) | Novel prmt5 inhibitors | |
| KR102396930B1 (ko) | 피리도[3,4-d]피리미딘 유도체 및 이를 포함하는 치료용 약학 조성물 | |
| US11242334B2 (en) | Heterocyclic compounds as kinase inhibitors, compositions comprising the heterocyclic compound, and methods of use thereof | |
| CN114599361B (zh) | Prmt5抑制剂的药物组合物 | |
| WO2022115377A1 (en) | Tricyclic carboxamide derivatives as prmt5 inhibitors | |
| JP2013523884A5 (cg-RX-API-DMAC7.html) | ||
| JPWO2020122093A5 (cg-RX-API-DMAC7.html) | ||
| NZ630467A (en) | Substituted pyrrolopyrimidine compounds, compositions thereof, and methods of treatment therewith | |
| JP2012528828A5 (cg-RX-API-DMAC7.html) | ||
| JP2019514878A5 (cg-RX-API-DMAC7.html) | ||
| RU2014130125A (ru) | Новые пиррольные соединения, способ их получения и фармацевтические композиции, содержащие их | |
| JPWO2021107160A5 (cg-RX-API-DMAC7.html) | ||
| KR20140014149A (ko) | 세린/트레오닌 키나제 저해제로서의 신규 아자인돌릴페닐 설폰아미드 | |
| RU2015149937A (ru) | Соединения для модулирования киназы и показания к их применению | |
| EP2356116A1 (en) | Substituted pyrroloý2,3-b¨-pyridines and-pyrazines | |
| NZ596487A (en) | 1H-IMIDAZO[4,5-c]QUINOLINONE DERIVATIVES AND THE USE THEREOF AS PI3K INHIBITORS | |
| ME02838B (me) | 3,4-dihidroizokinolin-2(1h)-ilni spojevi | |
| JP2016531858A5 (cg-RX-API-DMAC7.html) | ||
| RU2010128221A (ru) | Соединения тиенопиридазина, их получение, содержащие их фармацевтические композиции и их применение | |
| EP4598916A1 (en) | Heterocyclic inhibitors of kras g12c mutant proteins and uses thereof | |
| KR20150038466A (ko) | 다이옥시노- 및 옥사진-[2,3-d]피리미딘 pi3k 억제제 화합물 및 사용 방법 | |
| JP2008517913A5 (cg-RX-API-DMAC7.html) |